Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics (Premium)
$25.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medisana AG adjusts FY 2013 outlook with EBIT outlook below analysts' estimates and gives FY 2014 outlook in line with analysts' estimates


Friday, 11 Apr 2014 08:09am EDT 

Medisana AG:Says on basis of preliminary FY 2013 results, Management Board no longer assumes that EBIT operating earnings have improved compared with FY 2012, despite slight sales revenue growth that group achieved.Reasons for this include price reductions in company's business with customers.These price reductions were larger than in previous year, and also higher than forecast.Further reasons included adjustments applied during annual stocktaking to valuation of inventories due to technological further-developments, and recognition of income from partner agreement that was postponed until first half of 2014.Anticipates EBIT loss of around -3.1 million euros for FY 2013 (previous year: EBIT loss of -2.4 million euros).Anticipates as far as FY 2014 is concerned, that sales revenue to grow slightly year-on-year, and that operating earnings to report significant improvement.FY 2013 EBIT estimate -0.70 million euros - Thomson reuters I/B/E/S.FY 2014 EBIT estimate 0.80 million euros - Thomson reuters I/B/E/S.FY 2012 revenue of 41.8 million euros.FY 2013 revenue estimate 42.50 million euros - Thomson reuters I/B/E/S.FY 2014 revenue estimate 47.50 million euros - Thomson reuters I/B/E/S. 

Company Quote

2.352
0.0050 +0.21%
26 Aug 2014